Endogenous
lectins have the capacity to translate
glycan-encoded information on the cell surface into effects on cell growth. As test cases to examine changes in
protein presence associated with
tumor growth inhibition, we applied SILAC-based proteomics on human colon
carcinoma cells treated with
galectin-4 (Gal-4). The five tested lines-LS 180, Vaco 432, Colo 205, CX 1, and HCT 116-responded with differentiation and reduced proliferation to Gal-4 binding. In proteomic analysis (mass spectral data deposited with PRIDE, PXD003489), 2654
proteins were quantified, of which 190 were down-regulated and 115 were up-regulated (>2-fold). 1D annotation analysis of the results indicated down-regulation of DNA replication-associated processes, while
protein presence for secretory and transport functions appeared increased. The strongest induction was found for CALB2 (
calretinin; ∼24-fold), TGM2 (
protein-
glutamine γ-glutamyltransferase 2; ∼11-fold), S100A3 (∼10-fold), and GSN (
gelsolin; 9.5-fold), and the most pronounced decreases were seen for CDKN2A (
tumor suppressor ARF; ∼6-fold),
EPCAM (
epithelial cell adhesion molecule; ∼6-fold), UBE2C (
ubiquitin-conjugating enzyme E2 C; ∼5-fold), KIF2C (
kinesin-like
protein KIF2C; 5-fold), and LMNB1 (
lamin-B1; ∼5-fold). The presence of the common proliferation marker Ki-67 was diminished about 4-fold. By tracing significant alterations of
protein expression likely relevant for the observed phenotypic effects, the capacity of a
galectin to affect the
proteome of human
colon cancer cells at multiple sites is revealed.